{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-010286","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.037574+00:00","generated_at":"2026-06-17T13:32:53.876164+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biomea Fusion reports FY2022 net loss of $81.8M; cash $113.4M; clinical progress across three trials","bullets":["Net loss $25.3M in Q4 2022 ($14.7M in Q4 2021); full-year loss $81.8M vs $41.6M in 2021.","Cash, equivalents, and investments $113.4M at Dec 31, 2022, down from $175.7M a year earlier.","R&D expense $62.7M in FY2022 vs $28.0M; increase driven by clinical/preclinical development of BMF-219 and BMF-500.","BMF-219 advanced in three trials: COVALENT-101 (liquid tumors), COVALENT-102 (KRAS-mutant solid tumors), COVALENT-111 (type 2 diabetes); initial diabetes data reported March 2023.","IND for BMF-500 (FLT3 inhibitor) on track for H1 2023; third development candidate from FUSION platform expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-010286","json":"https://secwatch.observer/filing/0000950170-23-010286.json","markdown":"https://secwatch.observer/filing/0000950170-23-010286.md","text":"https://secwatch.observer/filing/0000950170-23-010286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023010286/0000950170-23-010286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023010286/bmea-20230328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:32:53.876164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b65a72e5058b12257aa1df2fefcad765089ab347","claim":"Biomea Fusion, Inc. reported financial results for the quarter ended and year ended December 31, 2022.","evidence_excerpt":"On March 28, 2023, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000095017023010286/0000950170-23-010286-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}